AstraZeneca and Merck announced the European Commission has approved Lynparza as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, and who have HER2-negative locally advanced or metastatic breast cancer.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
